UPDATE: Oppenheimer Starts Bio Blast Pharma (ORPN) at Outperform, Price Target $32
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
UPDATE: Roth Capital Starts Bio Blast Pharma (ORPN) at Buy
August 25, 2014 6:40 AM EDT(Updated - August 25, 2014 8:37 AM EDT)
Roth Capital initiated coverage on Bio Blast Pharma (NASDAQ: ORPN) with a Buy rating and a price target of $15.00. Analyst Joseph Pantginis anticipates a number of catalysts over the next 12-18 months.... More
